Perfuse Therapeutics Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
Perfuse Therapeutics is a clinical-stage biotechnology company focused on protecting and improving vision in ocular diseases, with the aim of reducing blindness. It is based in San Francisco, California, and operates within the biotechnology research industry. Its lead program, PER-001, is an intravitreal implant delivering a slow-release endothelin receptor antagonist intended for ischemia-related ocular diseases; the FDA cleared an IND for a Phase 1/2a study in 2023. In mid-2026, press coverage notes the company is developing a low-molecular-weight endothelin receptor antagonist with delayed drug release for glaucoma and diabetic retinopathy.